Sutro Biopharma Inc [STRO] stock prices are up 4.74% to $1.99 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The STRO shares have gain 4.74% over the last week, with a monthly amount glided 3.11%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Sutro Biopharma Inc [NASDAQ: STRO] stock has seen the most recent analyst activity on May 08, 2024, when BofA Securities initiated its Buy rating and assigned the stock a price target of $12. Previously, Deutsche Bank started tracking the stock with Buy rating on November 09, 2023, and set its price target to $12. On October 06, 2023, Oppenheimer initiated with a Outperform rating and assigned a price target of $10 on the stock. Wells Fargo downgraded its rating to a Equal Weight and decreased its price target to $8 on March 21, 2023. H.C. Wainwright started tracking with a Buy rating for this stock on June 18, 2021, and assigned it a price target of $35. In a note dated December 03, 2020, Stifel initiated an Buy rating and provided a target price of $25 on this stock.
The stock price of Sutro Biopharma Inc [STRO] has been fluctuating between $1.67 and $6.13 over the past year. Currently, Wall Street analysts expect the stock to reach $13 within the next 12 months. Sutro Biopharma Inc [NASDAQ: STRO] shares were valued at $1.99 at the most recent close of the market. An investor can expect a potential return of 553.27% based on the average STRO price forecast.
Analyzing the STRO fundamentals
The Sutro Biopharma Inc [NASDAQ:STRO] reported sales of 160.96M for trailing twelve months, representing a drop of -49.66%. Gross Profit Margin for this corporation currently stands at 0.59% with Operating Profit Margin at -0.81%, Pretax Profit Margin comes in at -0.67%, and Net Profit Margin reading is -0.77%. To continue investigating profitability, this company’s Return on Assets is posted at -0.27, Equity is -0.97 and Total Capital is -0.41. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.22.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.9167 points at the first support level, and at 1.8433 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.0317, and for the 2nd resistance point, it is at 2.0733.
Ratios To Look Out For
It’s worth pointing out that Sutro Biopharma Inc [NASDAQ:STRO]’s Current Ratio is 3.09. In addition, the Quick Ratio stands at 3.09 and the Cash Ratio stands at 1.33. Considering the valuation of this stock, the price to sales ratio is 1.02, the price to book ratio is 1.47.
